Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas

Virchows Archiv

Volumn 462, Issue 2, 2013, Pages 211-217

  De Vries, Maurits ^a   Bruijn, Inge Briaire De ^a   Cleton Jansen, Anne Marie ^a   Malessy, Martijn J A ^a   Van Der Mey, Andel G L ^a   Hogendoorn, Pancras C W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

BRAF; Growth; MAPK ERK; Vestibular schwannoma

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ACOUSTIC NEURINOMA; ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; CELL PROLIFERATION; GENETICS; MIDDLE AGED; MUTATION; NERVE TUMOR; NEUROMA; NUCLEOTIDE SEQUENCE; PATHOLOGY; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CELL PROLIFERATION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, NERVE TISSUE; NEUROMA, ACOUSTIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84877111524     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1342-8     Document Type: Article

References (56)

1. Mautner VF, Nguyen R, Kutta H et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14-18
2. Seizinger BR, Martuza RL, Gusella JF (1986) Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 322:644-647
3. Rouleau GA, Merel P, Lutchman M et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515-521
4. Trofatter JA, MacCollin MM, Rutter JL et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800
5. Golovnina K, Blinov A, Akhmametyeva EM et al (2005) Evolution and origin of merlin, the product of the neurofibromatosis type 2 (NF2) tumor-suppressor gene. BMC Evol Biol 5:69
6. Aarhus M, Bruland O, Saetran HA et al (2010) Global gene expression profiling and tissue microarray reveal novel candidate genes and down-regulation of the tumor suppressor gene CAV1 in sporadic vestibular schwannomas. Neurosurgery 67:998-1019
7. Irving RM, Moffat DA, Hardy DG et al (1994) Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 3:347-350
8. Jacoby LB, MacCollin M, Barone R et al (1996) Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer 17:45-55
9. Sainz J, Huynh DP, Figueroa K et al (1994) Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 3:885-891
10. Lekanne Deprez RH, Bianchi AB, Groen NA et al (1994) Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 54:1022-1029
11. Hadfield KD, Smith MJ, Urquhart JE et al (2010) Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas. Oncogene 29:6216-6221
12. Gutmann DH, Giordano MJ, Fishback AS et al (1997) Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 49:267-270
13. Hitotsumatsu T, Iwaki T, Kitamoto T et al (1997) Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 93:225-232
14. Huynh DP, Mautner V, Baser ME et al (1997) Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J Neuropathol Exp Neurol 56:382-390
15. Kino T, Takeshima H, Nakao M et al (2001) Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 6:441-454
16. Kullar PJ, Pearson DM, Malley DS et al (2010) CpG island hypermethylation of the neurofibromatosis type 2 (NF2) gene is rare in sporadic vestibular schwannomas. Neuropathol Appl Neurobiol 36:505-514
17. Serrano C, Simonetti S, Hernandez J et al (2010) BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors. J Clin Oncol 28:15s (abstract)
18. Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397-405
19. Dahiya S, Yu J, Kaul A et al (2012) Novel BRAF alteration in a sporadic pilocytic astrocytoma. Case Report Med 2012:418672
20. Lin A, Rodriguez FJ, Karajannis MA et al (2012) BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 71:66-72
21. Basto D, Trovisco V, Lopes JM et al (2005) Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol 109:207-210
22. Jeuken J, van den Broecke C, Gijsen S et al (2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 114:121-133
23. Perrone F, Da RL, Orsenigo M et al (2009) PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol 11:725-736
24. Fraenzer JT, Pan H, Minimo L Jr et al (2003) Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 23:1493-1500
25. Morrison H, Sperka T, Manent J et al (2007) Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67:520-527
26. Lim JY, Kim H, Kim YH et al (2003) Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway. Biochem Biophys Res Commun 302:238-245
27. Chadee DN, Xu D, Hung G et al (2006) Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci USA 103:4463-4468
28. Zhou L, Hanemann CO (2012) Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett 586:1403-1408
29. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
30. Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93:53-62
31. McCubrey JA, Steelman LS, Chappell WH et al (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284
32. Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319
33. Montagut C, Settleman J (2009) Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283:125-134
34. Fiirgaard B, Pedersen CB, Lundorf E (1997) The size of acoustic neuromas: CT and MRI. Neuroradiology 39:599-601
35. van Eijk R, Licht J, Schrumpf M et al (2011) Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One 6:e17791
36. Saldanha G, Purnell D, Fletcher A et al (2004) High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 111:705-710
37. Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21(Suppl 2):S16-S22
38. Jancik S, Drabek J, Radzioch D et al (2010) Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010:150960
39. Ligresti G, Militello L, Steelman LS et al (2009) PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8:1352-1358
40. Endo K, Konishi A, Sasaki H et al (2005) Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50:375-384
41. Boldrini L, Gisfredi S, Ursino S et al (2007) Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol 2:1086-1090
42. Carotenuto P, Roma C, Rachiglio AM et al (2010) Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11:1169-1179
43. Smith GD, Zhou L, Rowe LR et al (2011) Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens. Acta Cytol 55:576-583
44. Jiang W, Wang W, Fu F et al (2012) A more sensitive platform for the detection of low-abundance BRAF(V600E) mutations. Mol Cell Biochem 366(1-2):49-58
45. Yancovitz M, Litterman A, Yoon J et al (2012) Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 7:e29336
46. Wong CW, Fan YS, Chan TL et al (2005) BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 58:640-644
47. Zuidervaart W, Van NF, Stark M et al (2032) Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 92:2032-2038
48. Sturgis EM, Woll SS, Aydin F et al (1996) Epidermal growth factor receptor expression by acoustic neuromas. Laryngoscope 106:457-462
49. Prayson RA, Yoder BJ, Barnett GH (2007) Epidermal growth factor receptor is not amplified in schwannomas. Ann Diagn Pathol 11:326-329
50. Curto M, Cole BK, Lallemand D et al (2007) Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol 177:893-903
51. Wallace AJ, Watson CJ, Oward E et al (2004) Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test 8:368-380
52. Gonzalez-Gomez P, Bello MJ, Alonso ME et al (2003) CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas. Clin Cancer Res 9:5601-5606
53. Sastre L (2011) New DNA sequencing technologies open a promising era for cancer research and treatment. Clin Transl Oncol 13:301-306
54. Ku CS, Naidoo N, Wu M et al (2011) Studying the epigenome using next generation sequencing. J Med Genet 48:721-730
55. de Vries M, Hogendoorn PC, Briaire-de Bruijn I et al (2012) Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Arch 460(6):629-636
56. Allen M, Louise JJ (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223:162-176